FXR: a target for cholestatic syndromes?

  title={FXR: a target for cholestatic syndromes?},
  author={Shi-Ying Cai and James Boyer},
  journal={Expert opinion on therapeutic targets},
  volume={10 3},
The nuclear farnesoid X receptor (FXR) plays a pivotal role in maintaining bile acid homeostasis by regulating key genes involved in bile acid synthesis, metabolism and transport, including CYP7A1, UGT2B4, BSEP, MDR3, MRP2, ASBT, I-BABP, NTCP and OSTalpha-OSTbeta in humans. Altered expression or malfunction of these genes has been described in patients with cholestatic liver diseases. This review examines the rationale for the use of FXR ligand therapy in various cholestatic liver disorders and… CONTINUE READING